Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Natco Pharma / India

Natco Pharma & India

4 shared events · Importance 3 · Last updated Mar 31, 2026

Importance
3
Shared Events
4
Actions
0
Sentiment
50.0
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
Shared Events (4)
37
Business
Novo Nordisk Cuts Wegovy Price in India
Natco Pharma: Natco Pharma is one of the Indian generic drugmakers that will likely offer lower-priced versions of semaglutide once the patent expires.
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Nov 11, 2025 · 6 articles
0
Business
Novo Nordisk Semaglutide Patent Expiry in India
Natco Pharma: Natco Pharma is a key player in launching generic semaglutide in India at a significantly lower price, aiming to capture a substantial share of the weight-loss drug market.
Mar 20, 2026 · 8 articles
0
Business
Novo Nordisk Cuts Ozempic, Wegovy Prices in India
Natco Pharma: Natco Pharma is one of several Indian companies that launched generic versions of semaglutide, increasing competition for Novo Nordisk.
Mar 30, 2026 · 8 articles
0
Business
Venture Catalysts Exits Pee Safe
Natco Pharma: Natco Pharma continues to be an investor in Pee Safe.
Mar 17, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how Natco Pharma and India interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.